KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Switching Patients With Congenital Adrenal Hyperplasia to Modified-Release Hydrocortisone Capsules: Relative Bioavailability and Disease Control.

Richard John M Ross, Wiebke Arlt, Aude Brac de la Perriere, Angelica Lindén Hirschberg, Anders Juul, Deborah P Merke, John D C Newell-Price, Alessandro Prete, D Aled Rees, Nicole Reisch, Monica Stikkelbroeck, Philippe A Touraine, Kerry Maltby, Jo Quirke, Helen Coope, John Porter

Clin Endocrinol (Oxf) 103(3) 290-293

PMID40377230
PMCIDPMC12319290
DOI10.1111/cen.15275
发表日期2025-05-16
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:ROC 图;Figure 2:ROC 图。
摘要

摘要

BACKGROUND: Replacement therapy with modified-release hydrocortisone capsules (MRHC) restores the physiological circadian cortisol rhythm in congenital adrenal hyperplasia (CAH). AIMS: To determine the relative bioavailability of MRHC and evaluate an optimal protocol to switch CAH patients from standard therapy to MRHC. METHODS: (1): Crossover study in healthy participants comparing relative bioavailability of MRHC with immediate-release hydrocortisone (IRHC). (2): Post hoc analysis of first 4 weeks of phase 3 MRHC study when CAH patients were switched to MRHC. RESULTS: Twenty-four healthy male participants completed the relative bioavailability study: 20 mg MRHC showed comparable bioavailability to 20 mg IRHC tablets; mean AUC0-inf was 2650 versus 2450 h*nmol/L, ratio of 108% (90% confidence interval (CI) 103%-113%). In the phase 3 study, 122 CAH patients were recruited of which 63 patients were managed with IRHC alone at baseline; 31 of 63 were randomised to continue IRHC and 32 of 63 were randomised to switch to MRHC on the same daily dose but given twice daily. At 4 weeks, a greater reduction in both the 09:00 h 17-hydroxyprogesterone and androstenedione was observed in the MRHC group compared to the IRHC group; p < 0.001 and p = 0.01, respectively. CONCLUSIONS: MRHC showed comparable bioavailability to IRHC based on cortisol AUC after 20 mg administration. Switching patients treated with IRHC to a twice daily MRHC regimen on the same daily dose (giving approximately two thirds of the dose at night) is an effective protocol for starting MRHC treatment.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 Baseline corrected cortisol profiles in 24 dexamethasone suppressed healthy males after oral intake of 20 mg modified‐release hydrocortisone capsules (MRHC) and immediate‐release hydrocortisone tablets (IRHC), respectively.
非 KM Figure
Figure 2Figure 2 09:00 h serum 17OHP and A4 at baseline all on immediate‐release hydrocortisone tablets (IRHC) and after 4 weeks treatment with either modified‐release hydrocortisone capsules (MRHC) ( n = 32) or IRHC ( n = 31).
非 KM Figure